AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 311 min read$JAZZ

Iannone Robert sold $19.2M of JAZZ

Iannone Robert (EVP, Global Head of R&D & CMO) sold 76,921 shares of Jazz Pharmaceuticals plc (JAZZ) at an average of $249.70 ($247.86–$252.76, $19.21M total) across 6 trades on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Iannone Robert
Published Aug 31, 2026, 10:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$JAZZ
Bearish
medium confidence
Mentioned
$JAZZ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JAZZBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which can influence short‑term trading decisions.

02

Market read

First‑report insider sell of $19M; modest but material for a mid‑cap biotech.

03

What to watch

The 10b5-1 plan may have been set up before any material news, reducing informational value.

Relevance 6/10Novelty 8/10Timing: post‑market Aug 27 transaction, filed Aug 31

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$JAZZBearishMedium confidence
Context

EVP of R&D sold 76,921 shares for $19.2M via 10b5-1 plan on Aug 27, reducing his stake to 65,686 shares.

Expected impact

Possible short-term dip of 2‑4% as market digests the large insider sale.

Evidence & confidence

The sale size is material for a mid‑cap biotech and was executed through a pre‑arranged plan, suggesting a deliberate reduction of exposure.

Market effects

Sector

May raise questions about pipeline confidence within the pharma/biotech sector.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond Jazz Pharmaceuticals shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Company
    Jazz Pharmaceuticals plc

    UK‑based biopharma listed on NASDAQ under ticker JAZZ.

  • Executive
    Robert Iannone

    EVP, Global Head of R&D & CMO at Jazz Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JAZZ insider trading history →

Related articles

SEP 4
$JAZZHighAI 9/10

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy showed a statistically significant overall survival benefit over trastuzumab in the Phase 3 HERIZON-GEA-01 trial. The study involved 914 patients across 30+ countries. The FDA approved Ziihera for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, providing a commercial pathway. However, the magnitude of the survival benefit and safety concerns remain key factors for adoption.

insidermonkey.com3 min
SEP 2
$JAZZMedAI 8/10

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Jazz Pharmaceuticals (JAZZ) shares fell 6.9% since its last earnings report. Q2 2026 adjusted EPS missed estimates at $5.71, but revenues rose 16% YoY to $1.21B, beating expectations. The company raised 2026 revenue guidance to $4.60-$4.75B. Xywav sales grew 13% YoY, while Xyrem sales declined 14% YoY. Oncology sales increased 32% YoY, driven by Zepzelca's 42% growth.

finance.yahoo.com2 min
SEP 2
$JAZZHighAI 8/10

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals announced that zanidatamab plus chemotherapy showed improved overall survival in HER2+ advanced GEA patients compared to trastuzumab, per HERIZON-GEA-01 trial results. The HR for OS improved with longer follow-up. The FDA approved zanidatamab in August 2026 for first-line treatment, supported by earlier trial data. Jazz plans to present updated data at a medical meeting and submit findings to global health authorities.

cancernetwork.com2 min
AUG 31
$JAZZMedAI 8/10

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Jazz Pharmaceuticals (JAZZ) shares rose 2.5% after positive Phase 3 trial results for Ziihera combined with chemotherapy in advanced gastroesophageal adenocarcinoma. The trial showed a statistically significant overall survival benefit, reinforcing the drug's potential. The stock closed at $250.79, up 2.6% from the previous close. JAZZ is up 44.8% year-to-date and near its 52-week high of $261.62.

financialcontent.com2 min
AUG 31
$JAZZHighAI 8/10

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals (JAZZ) reported that Ziihera, combined with chemotherapy, showed statistically significant overall survival benefits in a Phase 3 trial for HER2+ advanced gastroesophageal adenocarcinoma (GEA). The results support Ziihera as a new standard of care, following its recent FDA approval. The company plans to present the data at a major medical meeting in Q4 2026.

prnewswire.com2 min